QLi5 Therapeutics will become a Global Top Proteasome Inhibitor Specialty Biotech based upon
QLi5 Therapeutics is a Network of several well known Korean and German Biotech and Institutions
World renowned basic research institute in Germany
Prof. Robert Huber Nobel laureate, emeritus director of the Max Planck Institute for Biochemistry
History & Testimonials
QLi5 Therapeutics was founded in January 2020 by Qurient Co. Ltd, (Korea – Majority Shareholder), Lead Discovery Center GmbH (LDC – Germany), Max-Planck-Gesellschaft (MPG – Germany) and Nobel laureate Robert Huber.